The Munich Private Equity team advised 908 Devices (Nasdaq: MASS) on its acquisition of TRACE Analytics GmbH.
With the acquisition of TRACE Analytics GmbH, 908 Devices expects a measurable step forward in its goal to build a connected and comprehensive bioanalytics platform.
908 Devices is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications.
TRACE Analytics GmbH develops online aseptic sampling systems and novel biosensors for bioreactor monitoring and control.
The Goodwin team was led by partner Dr. Jan Schinköth (Private Equity, Munich) and included partners Dr. Oded Schein (Tax, Munich), Sarah Jordan (Antitrust & Competition, London), Michael Minahan (Capital Markets, Boston) and Mark Macenka (Corporate, Boston), counsel Simone Waterbury (Antitrust & Competition, Boston), and associates Christoph Hempel (Private Equity, Munich) as well as Alison Finneran and Brady Cummins (Antitrust & Competition, Washington, D.C.).
For more details, read the press release.